Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy D Gilligan

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2003
Cancer survivorship issues for minority and underserved populationsTimothy D Gilligan, Marilyn A Carrington, Thomas P Sellers, et al.
The Journal of Urology|August 19, 2007
Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migrationHadley M Wood, Alwyn M Reuther, Timothy D Gilligan, et al.
Urology|October 12, 2011
Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009Andrew J Stephenson, Armen G Aprikian, Timothy D Gilligan, et al.
Journal of Kidney Cancer and VHL|September 4, 2024
Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical TrialsNathan Reynolds, Wei Wei, Kimberly Maroli, et al.
Journal of Oncology Practice|August 20, 2015
ReCAP: Feasibility and Effectiveness of a Pilot Program to Facilitate Quality Improvement Learning in Oncology: Experience of the American Society of Clinical Oncology Quality Training ProgramArif H Kamal, Doris Quinn, Timothy D Gilligan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysisCarvell T Nguyen, Alex Z Fu, Timothy D Gilligan, et al.
Eye (London, England)|February 6, 2026
Risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitorsNitesh Mohan, Sunil K Srivastava, Chandni Duphare, et al.
Eye (London, England)|June 25, 2026
Response to: "Comment on: risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors"Nitesh Mohan, Sunil K Srivastava, Chandni Duphare, et al.
Clinical Genitourinary Cancer|August 18, 2020
Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage MigrationIris Y Sheng, Wei Wei, Yu-Wei Chen, et al.
Cancer|December 6, 2011
Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcomeSarmad Sadeghi, Laurence Albiges, Laura S Wood, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2003
Cancer survivorship issues for minority and underserved populationsTimothy D Gilligan, Marilyn A Carrington, Thomas P Sellers, et al.
The Journal of Urology|August 19, 2007
Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migrationHadley M Wood, Alwyn M Reuther, Timothy D Gilligan, et al.
Urology|October 12, 2011
Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009Andrew J Stephenson, Armen G Aprikian, Timothy D Gilligan, et al.
Journal of Kidney Cancer and VHL|September 4, 2024
Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical TrialsNathan Reynolds, Wei Wei, Kimberly Maroli, et al.
Journal of Oncology Practice|August 20, 2015
ReCAP: Feasibility and Effectiveness of a Pilot Program to Facilitate Quality Improvement Learning in Oncology: Experience of the American Society of Clinical Oncology Quality Training ProgramArif H Kamal, Doris Quinn, Timothy D Gilligan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysisCarvell T Nguyen, Alex Z Fu, Timothy D Gilligan, et al.
Eye (London, England)|February 6, 2026
Risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitorsNitesh Mohan, Sunil K Srivastava, Chandni Duphare, et al.
Eye (London, England)|June 25, 2026
Response to: "Comment on: risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors"Nitesh Mohan, Sunil K Srivastava, Chandni Duphare, et al.
Clinical Genitourinary Cancer|August 18, 2020
Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage MigrationIris Y Sheng, Wei Wei, Yu-Wei Chen, et al.
Cancer|December 6, 2011
Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcomeSarmad Sadeghi, Laurence Albiges, Laura S Wood, et al.
Pageof 4